MedTrace Logo

The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)

NCT01551810 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2023-10-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and the immunogenicity of Influenza Virus Vaccine (Split Virion, Inactivated) that do not contains Preservative .

Conditions

Interventions

BIOLOGICAL

Influenza Virus Vaccine

Influenza Virus Vaccine 0.5ml intramuscular injections

BIOLOGICAL

Influenza Virus Vaccine(contains Preservative)

Influenza Virus Vaccine(contains Preservative)0.5ml intramuscular injections

Sponsors & Collaborators

  • Hebei Center for Disease Control and Prevention

    collaborator UNKNOWN

  • Institute of Medical Biology, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Guoyang Liao, Ph. D · Institute of Medical Biology, Chinese Academy of Medical Sciences

  • Yuliang Zhao, MD · Hubei Provincial Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
36 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2012-05-31
Completion
2012-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01551810 on ClinicalTrials.gov